T-Cell Lymphomas

We are close to the finalization

Monday, May 7, 2018

A pathobiology window in the “T-cell world”

Chairmen: E.S. Jaffe, S.A. Pileri

News from WHO

E.S. Jaffe

Defining vulnerabilities of PTCL

D.M. Weinstock

Standard treatment in front-line and prognostic index

Chairmen: F. Foss, S.M. Horwitz

How I treat:

PTCL

F.A. D'Amore

CTCL

Y.H. Kim

ATLL

K. Tsukasaki

NK/T-cell lymphoma

W.S. Kim

PET: to be or not to be?

B.D. Cheson

Prognostic models in PTCL

F. Foss

Tuesday, May 8, 2018

PTCL: morphology and pathobiology

Chairmen: B. Falini, M. Paulli

Molecular genotyping

T. Palomero

Gene expression profiling

J. Iqbal

ALCL

S.A. Pileri

The “CD30+ world”

Chairman: P.L. Zinzani

CD30 expression: is it a Rubik’s cube?

S.A. Pileri

Brentuximab vedotin in:

ALCL

B. Pro

PTCL-nos/AILT

S.M. Horwitz

CTCL

H.M. Prince

NK/T-cell lymphoma: SMILE and other “asparaginase” containing regimens

Chairmen: R. Advani, W.S. Kim

Experience in:

France

A. Jaccard

China

H. Huang

Korea

W.S. Kim

PTCL: update on...

Chairman: B.D. Cheson

Romidepsin

A.R. Shustov

Belinostat

F. Foss

Lenalidomide

S.M. Horwitz

Lectures

Chairman: A. Pinto

News on breast implant ALCL

H.M. Prince

PTCL: the new single agents

Chairmen: M. Ogura, E. Zucca

Aplidin

B. Pro

Duvelisib

S.M. Horwitz

PTCL

K. Tsukasaki

Wednesday, May 9, 2018

CTCL: morphology, pathobiology and prognostic models

Chairmen: E. Berti, S.A. Pileri

Histology

M. Santucci

Prognostic models

J. Scarisbrick

CTCL: conventional and emerging drugs

Chairmen: N. Pimpinelli, P. Quaglino

Histone deacetylase inhibitors

J. Scarisbrick

IPH4102 anti-KIR3DL2 mAb

M. Bagot

Duvelisib

S.M. Horwitz

Pembrolizumab

Y.H. Kim

Mogamulizumab: a pan-T cell lymphoma drug

Chairman: S.M. Horwitz

ATLL

K. Tsukasaki

Allotransplant setting

Chairman: F. Onida

North America

A.R. Shustov

Europe

P. Corradini

Europe

M. Bagot